Andrew S Kennedy Selected Research

Microspheres (Microsphere)

10/2022	Survival and Toxicities after 90Y Transarterial Radioembolization of Metastatic Colorectal Cancer in the RESIN Registry.
5/2021	ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies.
1/2021	Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
12/2015	Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.
4/2015	Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.
1/2015	A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof.
1/2012	Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
8/2011	Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies.
2/2011	Intra-arterial brachytherapy of hepatic malignancies: watch the flow.
9/2010	Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew S Kennedy Research Topics

Disease

25	Neoplasms (Cancer) 05/2021 - 02/2003
13	Neoplasm Metastasis (Metastasis) 10/2022 - 01/2006
8	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 03/2010
6	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 09/2004
6	Liver Neoplasms (Liver Cancer) 01/2012 - 10/2005
2	Adenocarcinoma 01/2017 - 01/2006
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/2016 - 06/2008
2	Necrosis 02/2011 - 01/2006
1	Ascites 04/2015
1	Fibrosis (Cirrhosis) 01/2014
1	Thrombosis (Thrombus) 09/2010
1	Melanoma (Melanoma, Malignant) 07/2009
1	Radiation Pneumonitis 10/2008
1	Breast Neoplasms (Breast Cancer) 11/2007
1	Liver Failure 03/2007
1	Drug-Related Side Effects and Adverse Reactions 01/2006
1	Fatigue 01/2006
1	Nausea 01/2006
1	Carcinoma (Carcinomatosis) 01/2006
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2006
1	Anorexia 01/2006
1	Colonic Neoplasms (Colon Cancer) 12/2004
1	Hepatitis 12/2004

Drug/Important Bio-Agent (IBA)

13	Yttrium-90IBA 05/2021 - 02/2003
4	SirtuinsIBA 05/2021 - 01/2006
3	Pharmaceutical PreparationsIBA 01/2015 - 01/2006
2	YttriumIBA 10/2022 - 01/2017
2	Bevacizumab (Avastin)FDA Link 01/2017 - 01/2014
1	Hemoglobins (Hemoglobin)IBA 02/2017
1	Carcinoembryonic AntigenIBA 01/2017
1	Indicators and Reagents (Reagents)IBA 01/2017
1	AlbuminsIBA 04/2015
1	Alkaline PhosphataseIBA 04/2015
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2015
1	Sorafenib (BAY 43-9006)FDA Link 01/2014
1	Biomarkers (Surrogate Marker)IBA 02/2011
1	Tumor Biomarkers (Tumor Markers)IBA 03/2007
1	Irinotecan (Camptosar)FDA LinkGeneric 06/2006
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2006
1	Docetaxel (Taxotere)FDA Link 01/2006
1	Cytotoxins (Cytolysins)IBA 10/2005

Therapy/Procedure

24	Microspheres (Microsphere) 10/2022 - 02/2003
14	Therapeutics 06/2017 - 02/2003
8	Drug Therapy (Chemotherapy) 02/2017 - 01/2006
7	Radiotherapy 05/2021 - 01/2006
4	Brachytherapy 05/2021 - 06/2006
2	Salvage Therapy 03/2010 - 06/2006
1	Surgical Instruments (Clip) 09/2010
1	Aftercare (After-Treatment) 06/2008
1	Radiofrequency Ablation 06/2008
1	Biological Therapy 01/2006
1	Adjuvant Chemotherapy 10/2005